CN113906026A - 作为atr激酶抑制剂的2,4,6-三取代的嘧啶化合物 - Google Patents

作为atr激酶抑制剂的2,4,6-三取代的嘧啶化合物 Download PDF

Info

Publication number
CN113906026A
CN113906026A CN202080040989.2A CN202080040989A CN113906026A CN 113906026 A CN113906026 A CN 113906026A CN 202080040989 A CN202080040989 A CN 202080040989A CN 113906026 A CN113906026 A CN 113906026A
Authority
CN
China
Prior art keywords
alkyl
haloalkyl
group
nrr
radical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080040989.2A
Other languages
English (en)
Inventor
赵焰平
王红军
刘彬
姜媛媛
仲伟婷
徐慧芬
张宏雷
黄闯闯
田娜娜
赵静
李晶
刘伟娜
周丽莹
刘亚男
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beijing Tide Pharmaceutical Co Ltd
Original Assignee
Beijing Tide Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Tide Pharmaceutical Co Ltd filed Critical Beijing Tide Pharmaceutical Co Ltd
Priority to CN202410650691.3A priority Critical patent/CN118619944A/zh
Publication of CN113906026A publication Critical patent/CN113906026A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

通式(A)化合物，它们可用于治疗ATR激酶介导的疾病，例如增生性疾病，例如癌症。还提供通式(A)化合物的药物组合物、其用于治疗ATR激酶介导的疾病的用途、及其制备。

Description

PCT国内申请，说明书已公开。

Claims (26)

  1. PCT国内申请，权利要求书已公开。
CN202080040989.2A 2019-06-06 2020-06-05 作为atr激酶抑制剂的2,4,6-三取代的嘧啶化合物 Pending CN113906026A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202410650691.3A CN118619944A (zh) 2019-06-06 2020-06-05 作为atr激酶抑制剂的2,4,6-三取代的嘧啶化合物

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
CN201910490080 2019-06-06
CN2019104900806 2019-06-06
CN201910876919X 2019-09-17
CN201910876919 2019-09-17
CN202010441539 2020-05-22
CN2020104415396 2020-05-22
PCT/CN2020/094532 WO2020244613A1 (zh) 2019-06-06 2020-06-05 作为atr激酶抑制剂的2，4，6-三取代的嘧啶化合物

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202410650691.3A Division CN118619944A (zh) 2019-06-06 2020-06-05 作为atr激酶抑制剂的2,4,6-三取代的嘧啶化合物

Publications (1)

Publication Number Publication Date
CN113906026A true CN113906026A (zh) 2022-01-07

Family

ID=73608860

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202010503909.4A Active CN112047938B (zh) 2019-06-06 2020-06-05 作为atr激酶抑制剂的2,4,6-三取代的嘧啶化合物
CN202410650691.3A Pending CN118619944A (zh) 2019-06-06 2020-06-05 作为atr激酶抑制剂的2,4,6-三取代的嘧啶化合物
CN202080040989.2A Pending CN113906026A (zh) 2019-06-06 2020-06-05 作为atr激酶抑制剂的2,4,6-三取代的嘧啶化合物

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CN202010503909.4A Active CN112047938B (zh) 2019-06-06 2020-06-05 作为atr激酶抑制剂的2,4,6-三取代的嘧啶化合物
CN202410650691.3A Pending CN118619944A (zh) 2019-06-06 2020-06-05 作为atr激酶抑制剂的2,4,6-三取代的嘧啶化合物

Country Status (7)

Country Link
US (1) US20220378799A1 (zh)
EP (1) EP3967694A4 (zh)
JP (1) JP7485701B2 (zh)
KR (1) KR20220016225A (zh)
CN (3) CN112047938B (zh)
TW (1) TWI778366B (zh)
WO (1) WO2020244613A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115043770A (zh) * 2022-07-21 2022-09-13 南京大学 一种吲哚/氮杂吲哚类化合物的光诱导合成方法

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115551860A (zh) * 2020-05-20 2022-12-30 北京泰德制药股份有限公司 作为atr激酶抑制剂的2,4,6-三取代的嘧啶化合物
CN114213424B (zh) * 2021-12-30 2023-05-26 杭州高光制药有限公司 一种呋喃[3，2-b]并吡啶衍生物的合成方法
CN115745995B (zh) * 2022-01-10 2024-09-03 苏州浦合医药科技有限公司 Atr抑制剂及其用途
WO2023215133A1 (en) * 2022-05-02 2023-11-09 AcuraStem Incorporated Pikfyve kinase inhibitors

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6251900B1 (en) * 1997-07-24 2001-06-26 Zenyaku Kogyo Kabushiki Kaisha Heterocyclic compounds and antitumor agent containing the same as active ingredient
WO2008032077A1 (en) * 2006-09-14 2008-03-20 Astrazeneca Ab Pyrimidine derivatives
WO2009093981A1 (en) * 2008-01-23 2009-07-30 S Bio Pte Ltd Triazine compounds as kinase inhibitors
CN101535296A (zh) * 2006-09-14 2009-09-16 阿斯利康(瑞典)有限公司 作为p13k和mtor抑制剂用于治疗增殖性疾病的2-苯并咪唑基-6-吗啉代-4-苯基嘧啶衍生物
US20110009405A1 (en) * 2009-07-07 2011-01-13 Pathway Therapeutics Limited Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
WO2019050889A1 (en) * 2017-09-08 2019-03-14 Bluevalley Pharmaceutical Llc SUBSTITUTED PYRROLOPYRIDINES AS ATR INHIBITORS
WO2019154365A1 (zh) * 2018-02-07 2019-08-15 南京明德新药研发有限公司 一种atr抑制剂及其应用
CN110467610A (zh) * 2018-05-10 2019-11-19 四川科伦博泰生物医药股份有限公司 一种取代嘧啶化合物、其制备方法和用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
GB0415364D0 (en) * 2004-07-09 2004-08-11 Astrazeneca Ab Pyrimidine derivatives
CN101765597A (zh) * 2007-04-12 2010-06-30 霍夫曼-拉罗奇有限公司 作为磷脂酰肌醇-3-激酶抑制剂的嘧啶衍生物
JP2010523637A (ja) * 2007-04-12 2010-07-15 エフ．ホフマン−ラ ロシュ アーゲー 医薬化合物
EP2411387B1 (en) * 2009-03-27 2015-08-19 VetDC, Inc. Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
WO2012044641A1 (en) * 2010-09-29 2012-04-05 Pathway Therapeutics Inc. 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
MA40933A (fr) * 2014-11-11 2017-09-19 Piqur Therapeutics Ag Difluorométhyl-aminopyridines et difluorométhyl-aminopyrimidines
CN110818690B (zh) * 2016-07-26 2021-08-10 深圳市塔吉瑞生物医药有限公司 用于抑制蛋白酪氨酸激酶活性的氨基嘧啶类化合物
CN111867590B (zh) * 2017-07-13 2023-11-17 德州大学系统董事会 Atr激酶的杂环抑制剂
JP7290627B2 (ja) * 2017-08-17 2023-06-13 ボード オブ レジェンツ，ザ ユニバーシティ オブ テキサス システム Ａｔｒキナーゼの複素環式阻害剤
EP3715343B1 (en) * 2017-12-21 2024-02-14 Shenzhen TargetRx, Inc. Diphenylaminopyrimidine compound for inhibiting kinase activity
CN110343095A (zh) * 2018-04-08 2019-10-18 中国科学院上海药物研究所 一类精氨酸甲基转移酶抑制剂及其药物组合物和用途
AU2020325416A1 (en) * 2019-08-06 2022-02-03 Wuxi Biocity Biopharmaceutics Co., Ltd. Crystalline form of ATR inhibitor and use thereof
CN115551860A (zh) * 2020-05-20 2022-12-30 北京泰德制药股份有限公司 作为atr激酶抑制剂的2,4,6-三取代的嘧啶化合物
WO2021238999A1 (zh) * 2020-05-29 2021-12-02 深圳市瓴方生物医药科技有限公司 氟代吡咯并吡啶类化合物及其应用

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6251900B1 (en) * 1997-07-24 2001-06-26 Zenyaku Kogyo Kabushiki Kaisha Heterocyclic compounds and antitumor agent containing the same as active ingredient
WO2008032077A1 (en) * 2006-09-14 2008-03-20 Astrazeneca Ab Pyrimidine derivatives
CN101535296A (zh) * 2006-09-14 2009-09-16 阿斯利康(瑞典)有限公司 作为p13k和mtor抑制剂用于治疗增殖性疾病的2-苯并咪唑基-6-吗啉代-4-苯基嘧啶衍生物
US20090325954A1 (en) * 2006-09-14 2009-12-31 Sam Butterworth 2-benzimidazolyl-6-morpholino-4-phenylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
WO2009093981A1 (en) * 2008-01-23 2009-07-30 S Bio Pte Ltd Triazine compounds as kinase inhibitors
US20110009405A1 (en) * 2009-07-07 2011-01-13 Pathway Therapeutics Limited Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
WO2019050889A1 (en) * 2017-09-08 2019-03-14 Bluevalley Pharmaceutical Llc SUBSTITUTED PYRROLOPYRIDINES AS ATR INHIBITORS
WO2019154365A1 (zh) * 2018-02-07 2019-08-15 南京明德新药研发有限公司 一种atr抑制剂及其应用
CN110467610A (zh) * 2018-05-10 2019-11-19 四川科伦博泰生物医药股份有限公司 一种取代嘧啶化合物、其制备方法和用途

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115043770A (zh) * 2022-07-21 2022-09-13 南京大学 一种吲哚/氮杂吲哚类化合物的光诱导合成方法
CN115043770B (zh) * 2022-07-21 2023-09-08 南京大学 一种吲哚/氮杂吲哚类化合物的光诱导合成方法

Also Published As

Publication number Publication date
TW202112764A (zh) 2021-04-01
KR20220016225A (ko) 2022-02-08
CN112047938B (zh) 2022-11-22
EP3967694A4 (en) 2022-12-07
TWI778366B (zh) 2022-09-21
JP2022536313A (ja) 2022-08-15
EP3967694A1 (en) 2022-03-16
WO2020244613A1 (zh) 2020-12-10
CN112047938A (zh) 2020-12-08
US20220378799A1 (en) 2022-12-01
JP7485701B2 (ja) 2024-05-16
CN118619944A (zh) 2024-09-10

Similar Documents

Publication Publication Date Title
CN115135636B (zh) 喹喔啉酮衍生物作为kras g12c突变蛋白的不可逆抑制剂
CN112047938B (zh) 作为atr激酶抑制剂的2,4,6-三取代的嘧啶化合物
TWI758832B (zh) 抑制並誘導降解egfr和alk的化合物
CN114829364B (zh) 抑制并诱导降解egfr激酶的化合物
CN108191857B (zh) 6-取代的吡啶并[2,3-d]嘧啶类化合物作为蛋白激酶抑制剂
CN113348170A (zh) 联苯类衍生物抑制剂、其制备方法和应用
TW202110831A (zh) 吡啶酮類衍生物、其製備方法及其在醫藥上的應用
WO2023134266A1 (zh) 2-哌啶基或2-吡唑基取代的嘧啶化合物作为egfr抑制剂
CN113929688B (zh) 作为atr激酶抑制剂的吡唑并嘧啶化合物
WO2023198180A1 (zh) Egfr降解剂
CN108137544B (zh) 用于抑制蛋白酪氨酸激酶活性的氨基嘧啶类化合物
CN112574208A (zh) 取代的稠合三环衍生物及其组合物及用途
JP7508593B2 (ja) Ａｔｒキナーゼ阻害剤としての２，４，６－トリ置換ピリミジン化合物
CN111349084B (zh) 用于抑制蛋白激酶活性的氨基嘧啶类化合物
CN117800922A (zh) Sos1抑制剂
CN112552348A (zh) 含硒化合物及其制备和应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40062003

Country of ref document: HK

RJ01 Rejection of invention patent application after publication

Application publication date: 20220107